Review Article

Hair Cell Protection from Ototoxic Drugs

Peng Wu, Xianmin Wu, Chunhong Zhang, Xiaoyun Chen, Yideng Huang, and He Li

Department of Otolaryngology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, 325000 Zhejiang Province, China

Correspondence should be addressed to Yideng Huang; huangyidengwz@yeah.net and He Li; lihewuyao@163.com

Received 29 March 2020; Accepted 28 June 2021; Published 12 July 2021

Copyright © 2021 Peng Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hearing loss is often caused by death of sensory hair cells (HCs) in the inner ear. HCs are vulnerable to a variety of different stresses, such as aging, acoustic trauma, genetic disorders, infection, and exposure to some ototoxic drugs. Unfortunately, the mammals only have very limited HC regeneration ability, and the death of HCs in mammals is irreversible, thus leading to permanent hearing deficit. Although hearing loss is not a life-threatening disease, it can affect the patient’s quality of life, especially in children, which will cause delays in language acquisition and dumb. That will cause significant burden on families and society.

Currently, the most effective and convenient protection is avoiding exposure to known ototoxic drugs. Although there are several drugs that can injure HCs, the most commonly encountered ototoxic drugs are the aminoglycosides (AGs) and the antineoplastic agent cisplatin. AGs are the most commonly prescribed antibiotics, such as gentamicin, amikacin, kanamycin, and neomycin, which are usually used in the treatment of infections caused by aerobic gram-negative bacteria. Cisplatin is a platinum-based chemotherapeutic drug, which is often used for the chemotherapy of malignant tumors. But the ototoxicity limits the clinical application of these two kinds of drugs. Both AGs and cisplatin can induce apoptotic cell death in HCs, especially the outer HCs of the basal turn.

HCs can undergo cell death through apoptosis and necrosis. But the most predominant form of drug-induced cell death is apoptosis. In order to protect HCs from cell death after ototoxic drug exposure, a better understanding of the mechanisms of aminoglycoside and cisplatin-induced hair cell death is required. Current studies of these apoptotic cell death mechanisms and potential targets of HC protection are discussed in this review.

1. Introduction

Hearing loss is the most common sensory impairment in humans. It is estimated that there were 466 million people living with hearing loss in 2018 [1]. Hearing loss is often caused by death of sensory hair cells (HCs) in the inner ear, which function in transducing the sound waves into electric signals. HCs are vulnerable to a variety of different stresses, such as aging, acoustic trauma, genetic disorders, infection, and exposure to some ototoxic drugs [2–6]. Unfortunately, the mammals only have very limited HC regeneration ability, and the death of HCs in mammals is irreversible, thus leading to permanent hearing deficit [13–18]. Although hearing loss is not a life-threatening disease, it can affect the patient’s quality of life, especially in children, which will cause delays in language acquisition and dumb. That will cause significant burden on families and society.

Currently, the most effective and convenient protection is avoiding exposure to known ototoxic drugs. Although there are several drugs that can injure HCs, the most commonly encountered ototoxic drugs are the aminoglycosides (AGs) and the antineoplastic agent cisplatin. AGs are the most commonly prescribed antibiotics, such as gentamicin, amikacin, kanamycin, and neomycin, which are usually used in the treatment of infections caused by aerobic gram-negative bacteria. Cisplatin is a platinum-based chemotherapeutic drug, which is often used for the chemotherapy of malignant tumors. But the ototoxicity limits the clinical application of these two kinds of drugs. Both AGs and cisplatin can induce apoptotic cell death in HCs, especially the outer HCs of the basal turn.

HCs can undergo cell death through apoptosis and necrosis. But the most predominant form of drug-induced cell death is apoptosis. In order to protect HCs from ototoxic insult, a better understanding of the mechanisms of aminoglycoside and cisplatin-induced hair cell death is required. Current studies of these apoptotic cell death mechanisms and potential targets of HC protection are discussed in this review.

2. Mechanism and Protection

2.1. Route of Ototoxic Drugs into Hair Cells. After systemic administration, ototoxic drugs can pass the blood-labyrinth barrier (BLB) and enter the endolymph via the Reissner’s membrane, especially via the stria vascularis [24]. After that, they enter into HCs and cause cell death.
Multiple pathways for entry of AGs and cisplatin into HCs exist. One pathway is endocytosis at the apical and synaptic poles of HCs, although direct evidence for its involvement in cytotoxicity has not been found [25, 26]. Transport through ion channels, especially mechanoelectrical transducer (MET) channel, is supposed to play an important role in AGs uptake into HCs [25–28]. Some researchers suggest AGs and cisplatin can enter the HCs through MET channel [25, 29, 30] or Copper Transporter 1 (CTR1) [31], respectively, which are located at the top of hair cell stereocilia. Other studies suggest that MET channel is also a major contributor to the entry of cisplatin into HCs, at least in the zebrafish [32, 33]. But a direct interaction between cisplatin and mammalian MET channels has not been reported. Some researchers reveal that cisplatin entry into cochlear and HCs is also mediated by organic cation transporter (OCT), and the expression of OCT2, an isoforms of OCT, has been detected in HCs, as well as in stria vascularis [31, 34]. There is also evidence for the participation of transient receptor potential (TRP) channels, a family of polymodal ion channels activated by a variety of physical and chemical stimuli, such as oxidative stress, tissue damage, and inflammation [28]. TRP channels, such as TRPA1, TRPV1, and TRPV4, are additional candidate aminoglycoside-permeant channels, and all of them are found expressed in the HCs [35–37]. Exposure to immunostimulatory lipopolysaccharides, to simulate of bacterial infections, increased the cochlear expression of TRPV1 and hair cell uptake of gentamicin, thus, exacerbate ototoxicity of AGs [38]. In murine cochlear cultures, when the MET channels were disabled, the activated TRPA1 channels will facilitate the uptake of gentamicin [37].

2.2. Efforts in Inhibiting the Uptake of Drugs. Avoiding ototoxic drugs entry into HCs is the primary step. On the level of the MET channel, there are two possibilities exist. The first one is steric modification of the chemical structure of drugs. The MET channel pore, which has a diameter at its narrowest part of at least 1.25–1.5 nm, is large enough to allow AGs to enter the hair cell cytosol [39]. Therefore, widening the AG diameter by binding of certain molecules appears a promising strategy to inhibit AGs passing through the MET channel. But this biding must be irrelevant for antimicrobial activity [40]. The second way is blocking the MET channel to prevent ototoxic drugs entering HCs, especially for AGs. MET channel blocker, such as ORC-13661, can protect HCs against both AGs and cisplatin [41]. Because blocking of the MET channel would prevent hair cell depolarization and affect hearing function, therefore, the blockage must be temporary [42, 43].

Myosin7a is supposed to mediate AG endocytosis, and the uptake of AGs was decreased in Myosin7a mutant mice. This indicate a promising target for HC protection [44].

Intratympanic administration of copper sulfate, a CTRI inhibitor, or knockdown of CTRI with small interfering RNA can decrease the uptake and cytotoxicity of cisplatin and prevent hearing loss caused by cisplatin, both in vitro and in vivo [31]. OCT knockout or inhibition of OCT with cimetidine protects HCs against cisplatin-induced ototoxicity [34].

3. The Involvement of Mitochondrial Dysfunction and DNA Damage

The entry of AGs into HCs can lead to mtDNA mutations and thus affect the RNA translation and protein synthesis within mitochondria [45] and therefore leading to a decrease in ATP synthesis. With the decrease of energy production, the mitochondrial membrane integrity is compromised and thus leading to the leakage of cytochrome c, the generation of reactive oxygen species (ROS), and activation of stress kinases [46, 47]. The accumulation of ROS and cytochrome c will lead to the activation of the upstream caspases and subsequent apoptotic cell death. On the other hand, both ROS and stress kinases can cause cell death directly, as well as by amplifying insults targeting the mitochondria. And ROS can also cause mtDNA defects.

As for cisplatin, the ototoxic mechanism has been shown to be associated with several factors, such as oxidative stress, DNA damage, and inflammatory cytokines. Several studies have implicated the mitochondrial pathways in the apoptosis of HCs after cisplatin administration [48]. Exposure to cisplatin can also cause excessive generation of ROS via the NADPH-oxidase (NOX) pathway [49, 50], which will activate the mitochondrial apoptosis pathway that mentioned above. The signal transducers and activators of transcription 1 (STAT1) is an important mediator of cell death, and the STAT1 phosphorylation was found in HCs after exposure to cisplatin. STAT1 is involved in the response to the release of ROS, inflammatory cytokines, and DNA damage [51].

All these mechanisms of drug-induced hair cell death and protection will be discussed below.

3.1. Reactive Oxygen Species. ROS are mainly generated by the mitochondria in mammalian cells. AGs can combine with iron salts, and the iron-AG complexes catalyze free radical reactions and lead to ROS generation [52]. As mentioned above, AGs decrease the ATP synthesis, which will increase the permeability of mitochondrial transmembrane and the leakage of cyt-c and ROS. The ROS can also generate via the NOX3 pathway after cisplatin exposure. The ROS overload leads to the depletion of the cochlear antioxidant enzyme system (e.g., superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase), which scavenges and neutralizes the generated superoxide and hydrogen peroxide [53]. The release of ROS causes further damage to mitochondrial components, such as mtDNA, mitochondrial membranes, and respiratory chain proteins, as well as nuclear DNA associated with mitochondrial function [54]. The ultimate effect of increased ROS generation is to promote apoptotic cell death, as described above.

3.2. Neutralization of Reactive Oxygen Species. Some studies have reported that antioxidants can promote HC survival in drug-induced ototoxicity, including coenzyme Q10 [55]; α-lipoic acid [56]; D-methionine [57]; thiourea [58]; vitamins
B, C, and E [59]; N-acetylcysteine (NAC) [60]; and hormone melatonin [61]. Knockdown of NOX3 by intratympanic delivery of short interfering RNA (siRNA) protects against cisplatin-induced HC death [62]. Reducing the expression of TRPV1 or NOX3 can inhibit the ROS generation and the transcription factor STAT1 activation. And STAT1 activation will promote proapoptotic actions of cisplatin [63]. This indicates the inhibition of TRPV1 or NOX3 as promising approaches for reducing cisplatin ototoxicity. Another candidate strategy is the use of iron chelators, 2,3-dihydroxybenzoate [64], and acetylsalicylate (ASA) [65], which can compete with AGs for iron binding.

However, effects of these long-term treatments remain to be studied.

3.3. Caspase-Mediated Apoptosis. It has generally been accepted that the ototoxic drug-induced hair cell death shares a common pathway: caspase activation.

Caspases are divided into upstream and downstream members, which are normally inactive by binding with inhibitor of apoptosis proteins (IAP) [66, 67]. The upstream caspases are activated by proapoptotic signals, such as cytochrome c [68, 69], p53 [49], antiapoptotic Bcl-2 proteins [70, 71], tumor necrosis factor (TNF) family [72], and nuclear factor kappa B (NF-kB) [73]. And the downstream caspases are activated by upstream caspases.

Caspase-8 is an upstream member, which is linked to membrane-associated death receptors. Caspase-8 can activate by ligands such as Fas or TNF-α and subsequently activate downstream caspases such as caspase-3, -6, and -7 [72, 74]. Although caspase-8 is activated in HCs after AG administration [75], inhibition of this pathway does not prevent HC death or prevent caspase-3 activation [76]. Thus, it does not play a key role in HC death.

Caspase-9 is also an upstream member, which is triggered by nonreceptor stimulation, such as cytokine c releasing from mitochondrial [69]. After activation, caspase-9 can cleave and activate downstream caspases-3, which eventually lead to apoptotic HC death [75]. Caspase-3 is a downstream member, which mediates apoptotic program by cleaving proteins necessary for cell survival, such as cytoskeletal proteins [77]. The cisplatin-induced activation of caspase-9 and caspase-3 was seen in HEI/OC1 cells [78] and UB/OC1 cells [79].

3.4. Inhibition of Caspase Members. Studies have shown that intracochlear administration with specific inhibitors of caspase-9 or caspase-3 can prevent AG-induced or cisplatin-induced HC death and hearing loss [48, 80]. Caspase inhibitors, such as z-VAD-FMK and z-LEHD-FMK, can protect HCs against AG-induced cell death [81, 82]. Intracochlear perfusions with caspase-3 inhibitor (z-DEVD-fmk) and caspase-9 inhibitor (z-LEHD-fmk) prevent hearing loss and loss of HCs in cisplatin treated guinea pigs [48]. Several other efforts targeting the different steps in caspase activation are also promising. For example, NF-κB inhibitors, such as Bay 11-7085 or SN-50, can inhibit cisplatin-induced caspase-3 activation and apoptosis in HEI/OC1 cells [78].

3.5. BCL-2 Family. The Bcl-2 family can be categorized as antiapoptotic (e.g., Bcl-2 and Bcl-XL) or proapoptotic (e.g., Bax, Bak, Bcl-Xs, Bid, Bad, and Bim) members [83, 84]. Antiapoptotic Bcl-2 members can bind to proapoptotic Bcl-2 members, which will neutralize the proapoptotic signal [85]. The balance between the antiapoptotic and proapoptotic members is crucial for the living of the cell. When the balance tilts to proapoptosis, the proapoptotic Bcl-2 members, such as Bax and Bid, will translocate from the cytoplasm to the mitochondria, which will increase the permeability of mitochondrial transmembrane and lead to the generation of ROS and leakage of cytochrome c into the cytoplasm, thus eventually activate caspase-9 and caspase-3 and lead to apoptotic cell death as mentioned above [86, 87]. Recently, the increased expression of Bax and the decreased expression of Bcl-XL were observed in UB/OC-1 cells after cisplatin treatment [79]. The overexpression of Bcl-2 can inhibit the release of cytochrome c, thereby inhibiting the apoptosis cascade. This has been confirmed by some researchers in cochlear cell line or mouse utricles following AGs or cisplatin exposure [48, 70, 88].

3.6. Efforts on Targeting the Bcl-2 Family. Targeting the Bcl-2 family as the upstream mediator of apoptosis can prevent AG-induced hair cell death. Some studies reveal that overexpression of the antiapoptotic Bcl-2 members can inhibit apoptotic hair cell death following AG exposure in vitro and in vivo [70, 87, 89], while epigallocatechin gallate (EGCG), a known inhibitor of STAT1, can reverse the balance of Bax and Bcl-XL to antiapoptotic, which will protect HCs against apoptosis after cisplatin administration [79].

3.7. The c-jun NH2-Terminal Kinases (JNKs). The c-jun NH2-terminal kinases (JNKs) are key modulators of apoptosis, which are activated in response to cellular insults, such as generation of ROS, in HCs treated with neomycin and cisplatin [90, 91]. JNK activation acts as upstream of cytochrome c redistribution and caspase activation [92, 93]. When activated, JNKs can activate the transcription factors c-Jun, c-FOS, ELK-1, and Bcl-2. After AG administration, the increased JNKs, c-Jun, c-FOS, and Bcl-2 have been observed in HCs [94–96].

3.8. Inhibitors of the JNK Pathway. JNK inhibitors such as CEP-1347 [97] and CEP 11004 [91] can attenuate hair cell loss following AG administration. But, JNK inhibitor does not protect HCs against cisplatin-induced cell death, nor does it prevent redistribution of cytochrome c [48].

The mechanisms of AG-induced and cisplatin-induced HC death are summarized in Figure 1.

3.9. Other Promising Targets. There are some other mechanisms underlying the ototoxic of AGs and cisplatin, such as heat shock proteins (HSP), p53, and NF-κB as well as calcium-dependent proteases, and so on. Researchers have achieved promising outcomes. For example, overexpression of HSP-70 in transgenic mice can protect HCs against both aminoglycoside- and cisplatin-induced hair cell death [98, 99]. It is indicated that p53 acts upstream of mitochondrial...
apoptotic pathway and downregulation of the p53 gene protects HCs from cisplatin-induced Bax translocation, caspase-3 activation, cytochrome c translocation, and cell death [100]. Although p53 inhibitor protects against cisplatin-induced ototoxicity, the systemic application will interfere with the anticancer efficacy of cisplatin, while it is revealed that the intratympanic application of p53 inhibitor, such as pfithrin-a, protects auditory function without compromising the anticancer efficacy of cisplatin [100]. It has been revealed that Wnt/β-catenin signaling has an important role in protecting HCs against neomycin-induced HC loss. The overexpression of β-catenin can reduce forkhead box O3 transcription factor (Foxo3) and Bim expression and ROS levels after neomycin exposure [11]. This might be a new therapeutic target. Some researchers used rapamycin, an autophagy activator, to increase the autophagy activity and found that the ROS levels, apoptosis, and cell death were significantly decreased after neomycin or gentamicin exposure, suggesting that autophagy might be correlated with AG-induced HC death [101]. It is also revealed that melofenamic acid can attenuate cisplatin-induced oxidative stress and apoptosis in HEI-OC1 cells, by inhibiting cisplatin-induced upregulation of autophagy [12].

3.10. Potential Drug Targets. With increased understanding of ototoxic cell death, a numerous of therapeutic efforts have been made to target different steps of in HC death. The HEI-OC1 and UB/OC-1 cell lines, organ explants, larval zebrafish lateral-line neuromasts, and some animal model (e.g., chicken, rat, mouse, and guinea pig) are the most commonly used research strategies. The delivery of test compounds can be performed by intratympanic, intraperitoneal, intramuscular, subcutaneous, intracochlear, and oral administration. Potential drug targets for treatment of AG and cisplatin ototoxicity are summarized in Table 1.
4. Conclusion

As discussed above, many efforts have been made to protect HCs from cell death after ototoxic drug exposure. The outcomes are promising, but risks also arise. For example, endotoxemia-mediated inflammation can enhance aminoglycoside trafficking across the BLB and potentiate AG-induced ototoxicity. This indicates that patients with severe infections are at greater risk of AG-induced hearing loss than previously recognized. Systemic interference with cell signal-

Table 1: Potential drug targets for treatment of AG and cisplatin ototoxicity.

| Compound         | Ototoxic drug | Mechanism                                      | Materials and methods                                      | References |
|------------------|---------------|-----------------------------------------------|------------------------------------------------------------|------------|
| ORC-13661        | AG and cisplatin | Block MET channel                              | Mouse cochlear cultures, *in vitro*                         | [41]       |
| Copper sulfate   | Cisplatin     | CTR1 inhibitor, inhibit uptake                 | HEI-OC1 cells, *in vitro*                                   | [31]       |
| Cimetidine       | Cisplatin     | OCT blocker, inhibit uptake                    | Mice, *in vivo*, i.t.                                      | [34]       |
| Coenzyme Q10     | Cisplatin     | Antioxidant                                    | Rat, *in vivo*, oral administrations                        | [55]       |
| α-Lipoic acid    | AG            | Antioxidant                                    | Guinea pigs, *in vivo*, i.m.                               | [56]       |
| D-Methionine     | AG            | Antioxidant                                    | Guinea pigs, *in vivo*, i.p.                               | [57]       |
| Thioareua        | Cisplatin     | Antioxidant                                    | Guinea pigs, *in vivo*, intracochlear perfusion by osmotic pump | [58]       |
| Vitamins B, C, and E | Cisplatin | Antioxidant                                    | Rat, *in vivo*, i.p.                                       | [59]       |
| N-Acetylcysteine | AG            | Antioxidant                                    | Rat, *in vivo*, i.p.                                       | [60]       |
| Hormone melatonin| Cisplatin     | Antioxidant                                    | Rat, *in vivo*, i.p.                                       | [61]       |
| siRNA            | Cisplatin     | Inhibit TRPV1 or NOX3 activation               | UB/OC-1 cells, *in vitro*                                   | [62]       |
| 2,3-Dihydroxybenzoate | AG    | Iron chelators                                | Guinea pigs, *in vivo*, i.p.                               | [64]       |
| Acetylsalicylate | AG            | AG for iron binding                            | Guinea pigs, *in vivo*, oral administration                | [65]       |
| EGCG             | Cisplatin     | STAT1 inhibitor, Antiapoptotic                 | Rat, *in vivo*, oral administrations                        | [79]       |
| Bay 11-7085      | Cisplatin     | NF-xB inhibitors, Inhibit caspase-3 activation | HEI/OC1 cells, *in vivo*                                   | [78]       |
| SN-50            | Cisplatin     | NF-xB inhibitors, Inhibit caspase-3 activation | HEI/OC1 cells, *in vivo*                                   | [78]       |
| z-VAD-FMK        | AG            | General caspase inhibitor                      | Guinea pigs, *in vivo*, intracochlear perfusion by osmotic pump | [81]       |
| z-LEHD-FMK       | AG            | Caspase-9 inhibitor                            | Guinea pigs, *in vivo*, intracochlear perfusion by osmotic pump | [81]       |
| z-DEVD-fmk       | Cisplatin     | Caspase-3 inhibitor                            | Guinea pigs, *in vivo*, intracochlear perfusion by minipump | [48]       |
| z-LEHD-fmk       | Cisplatin     | Caspase-9 inhibitor                            | Guinea pigs, *in vivo*, intracochlear perfusion by minipump | [48]       |
| CEP-1347         | AG            | JNK inhibitor                                  | Guinea pigs, *in vivo*, s.c.                               | [97]       |
| CEP 11004        | AG            | JNK inhibitor                                  | Chicken vestibular hair cell culture, *in vitro*           | [91]       |
| Piftthrin-a      | Cisplatin     | Inhibit mitochondrial apoptotic pathway        | Mouse cochlear culture, *in vitro*                         | [100]      |

AG: aminoglycoside; MET: mechanoelectrical transducer; CTR1: Copper Transporter 1; OCT: organic cation transporter; siRNA: short interfering RNA; TRP: transient receptor potential; NOX3: NADPH-oxidase 3; ROS: reactive oxygen species; STAT1: transcription factor; EGCG: epigallocatechin gallate; JNK: c-jun NH2-terminal kinase; i.t.: intratympanic; i.p.: intraperitoneal; i.m.: intramuscular; s.c.: subcutaneous.
transient benefit in preventing hearing loss [102]. As for AGs can remain in HCs for months, thus, use of a single antioxidant in high-risk human populations has not produced expected benefits; the outcomes of long-term and mixture administration with other drugs are also need to be well studied.

A variety kind of insults to the inner ear can cause HC death and hearing loss. Although the most predominant form of drug-induced cell death is apoptosis, necrotic features are also seen in HCs following AG exposure [19]. This suggests that the apoptotic and necrotic cell death that occurs in HCs may share among many ototoxic events, while the necrosis and associated pathways are still unclear in HCs after ototoxic drug exposure. Research in the mechanisms of regulated necrosis in HCs may improve our understanding of the complex communications between different signaling cascades. On the other side, great progresses have been made in the field of HC regeneration. For example, it has been reported that Lgr5-expressing cells can differentiate into HCs [17], and several genes have been identified that regulate the regeneration of HCs [13, 18]. These are also promising strategies.

Thus, a full understanding of the mechanisms in ototoxic drug-induced hearing loss still remains urgent, and the possibility of future clinical utilization is also need to be well evaluated.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

This research was jointly supported by the Zhejiang Provincial Natural Science Foundation of China and the Wenzhou basic scientific research project under Grant Nos. LY19H130003, LY19H130004, Y20H130015, and Y20180091.

References

[1] J. Guo, R. Chai, H. Li, and S. Sun, “Protection of hair cells from ototoxic drug-induced hearing loss,” Advances in Experimental Medicine and Biology, vol. 1130, pp. 17–36, 2019.
[2] Y. Liu, J. Qi, X. Chen, et al., “Critical role of spectrin in hearing development and deafness,” Science advances, vol. 5, no. 4, article eaav7803, 2019.
[3] Y. Wang, J. Li, X. Yao et al., “Loss of CIB2 causes profound hearing loss and abolishes mechanoelectrical transduction in mice,” Frontiers in Molecular Neuroscience, vol. 10, p. 401, 2017.
[4] C. Zhu, C. Cheng, Y. Wang et al., “Loss of ARHGEF6 causes hair cell stereocilia deficits and hearing loss in mice,” Frontiers in Molecular Neuroscience, vol. 11, p. 362, 2018.
[5] J. Qi, Y. Liu, C. Chu et al., “A cytoskeleton structure revealed by super-resolution fluorescence imaging in inner ear hair cells,” Cell Discovery, vol. 5, no. 1, p. 12, 2019.
[6] J. Qi, L. Zhang, F. Tan et al., “Espin distribution as revealed by super-resolution microscopy of stereocilia,” American Journal of Translational Research, vol. 12, no. 1, pp. 130–141, 2020.
[7] Z. H. He, S. Y. Zou, M. Li et al., “The nuclear transcription factor FoxG1 affects the sensitivity of mimetic aging hair cells to inflammation by regulating autophagy pathways,” Redox Biology, vol. 28, article 101364, 2020.
[8] S. Gao, C. Cheng, M. Wang et al., “Blebbistatin inhibits neomycin-induced apoptosis in hair cell-like HEI-OC1 cells and in cochlear hair cells,” Frontiers in Cellular Neuroscience, vol. 13, p. 590, 2019.
[9] Y. Zhang, W. Li, Z. He et al., “Pre-treatment with fasudil prevents neomycin-induced hair cell damage by reducing the accumulation of reactive oxygen species,” Frontiers in Molecular Neuroscience, vol. 12, p. 264, 2019.
[10] W. Liu, X. Xu, Z. Fan et al., “Wnt signaling activates TP53-induced glycosylation and apoptosis regulator and protects against cisplatin-induced spiral ganglion neuron damage in the mouse cochlea,” Antioxidants & Redox Signaling, vol. 30, no. 11, pp. 1389–1410, 2019.
[11] L. Liu, Y. Chen, J. Qi et al., “Wnt activation protects against neomycin-induced hair cell damage in the mouse cochlea,” Cell Death & Disease, vol. 7, no. 3, article e2136, 2016.
[12] H. Li, Y. Song, Z. He et al., “Meclofenamic acid reduces reactive oxygen species accumulation and apoptosis, inhibits excessive autophagy, and protects hair cell-like HEI-OC1 cells from cisplatin-induced damage,” Frontiers in Cellular Neuroscience, vol. 12, p. 139, 2018.
[13] S. Zhang, Y. Zhang, Y. Dong et al., “Knockdown of Foxg1 in supporting cells increases the trans-differentiation of supporting cells into hair cells in the neonatal mouse cochlea,” Cellular and Molecular Life Sciences, vol. 77, no. 7, pp. 1401–1419, 2020.
[14] F. Tan, C. Chu, J. Qi et al., “AAV-ie enables safe and efficient gene transfer to inner ear cells,” Nature Communications, vol. 10, no. 1, p. 3733, 2019.
[15] C. Cheng, Y. Wang, L. Guo et al., “Age-related transcriptome changes in Sox2+ supporting cells in the mouse cochlea,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 365, 2019.
[16] X. Lu, S. Sun, J. Qi et al., “Bmi1 regulates the proliferation of cochlear supporting cells via the canonical Wnt signaling pathway,” Molecular Neurobiology, vol. 54, no. 2, pp. 1326–1339, 2017.
[17] T. Wang, R. Chai, G. S. Kim et al., “Lgr5+ cells regenerate hair cells via proliferation and direct transdifferentiation in damaged neonatal mouse utricle,” Nature Communications, vol. 6, no. 1, p. 6613, 2015.
[18] B. C. Cox, R. Chai, A. Lenoir et al., “Spontaneous hair cell regeneration in the neonatal mouse cochlea in vivo,” Development, vol. 141, no. 4, pp. 816–829, 2014.
[19] C. T. Dinh, S. Goncalves, E. Bas, T. R. Van De Water, and A. Zine, “Molecular regulation of auditory hair cell death and approaches to protect sensory receptor cells and/or stimulate repair following acoustic trauma,” Frontiers in Cellular Neuroscience, vol. 9, p. 96, 2015.
[20] A. Li, D. You, W. Li et al., “Novel compounds protect auditory hair cells against gentamycin-induced apoptosis by maintaining the expression level of H3K4me2,” Drug Delivery, vol. 25, no. 1, pp. 1033–1043, 2018.
[21] S. Sun, M. Sun, Y. Zhang et al., “In vivo overexpression of X-linked inhibitor of apoptosis protein protects against neomycin-induced hair cell loss in the apical turn of the cochlea during the ototoxic-sensitive period,” Frontiers in Cellular Neuroscience, vol. 8, p. 248, 2014.
[22] Z. He, S. Sun, M. Waqas et al., “Reduced TRMU expression increases the sensitivity of hair-cell-like HEI-OC-1 cells to neomycin in vitro,” *Scientific Reports*, vol. 6, no. 1, article 29621, 2016.

[23] X. Yu, W. Liu, Z. Fan et al., “c-Myb knockdown increases the neomycin-induced damage to hair-cell-like HEI-OC1 cells in vitro,” *Scientific Reports*, vol. 7, article 41094, no. 1, 2017.

[24] Q. Wang and P. S. Steyger, “Trafficking of systemic fluorescent gentamicin into the cochlea and hair cells,” *Journal of the Association for Research in Otolaryngology*, vol. 10, no. 2, pp. 205–219, 2009.

[25] A. Alharazneh, L. Luk, M. Huth et al., “Functional hair cell mechanotransducer channels are required for aminoglycoside ototoxicity,” *PLoS One*, vol. 6, no. 7, article e22347, 2011.

[26] A. A. Vu, G. S. Nadaraja, M. E. Huth et al., “Integrity and regeneration of mechanotransduction machinery regulate aminoglycoside entry and sensory cell death,” *PLoS One*, vol. 8, no. 1, article e54794, 2013.

[27] E. Hashino and M. Shero, “Endocytosis of aminoglycoside antibiotics in sensory hair cells,” *Brain Research*, vol. 704, no. 1, pp. 135–140, 1995.

[28] B. Nilius and A. Szallasi, “Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine,” *Pharmacological Reviews*, vol. 66, no. 3, pp. 676–814, 2014.

[29] W. Marcotti, S. M. van Netten, and C. J. Kros, “The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mecha-electrical transducer channels,” *The Journal of Physiology*, vol. 567, no. 2, pp. 505–521, 2005.

[30] J. E. Gale, W. Marcotti, H. J. Kennedy, C. J. Kros, and G. P. Richardson, “FM1-43 dye behaves as a permeant blocker of the hair-cell mechanotransducer channel,” *The Journal of Neuroscience*, vol. 21, no. 18, pp. 7013–7025, 2001.

[31] S. S. More, O. Akil, A. G. Ianculescu, E. G. Geier, L. R. Lustig, and K. M. Giacomini, “Role of the copper transporter, CTR1, in platinum-induced ototoxicity,” *The Journal of Neuroscience*, vol. 30, no. 28, pp. 9500–9509, 2010.

[32] A. J. Thomas, D. W. Hailey, T. M. Statwicki et al., “Functional mechanotransduction is required for cisplatin-induced hair cell death in the zebrafish lateral line,” *The Journal of Neuroscience*, vol. 33, no. 10, pp. 4405–4414, 2013.

[33] S. Sheth, D. Mukherjea, L. P. Rybak, and V. Ramkumar, “Mechanisms of cisplatin-induced ototoxicity and otoprotection,” *Frontiers in Cellular Neuroscience*, vol. 11, p. 338, 2017.

[34] G. Carimbioli, D. Deuster, A. Knief et al., “Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions,” *The American Journal of Pathology*, vol. 176, no. 3, pp. 1169–1180, 2010.

[35] J. Zheng, C. Dai, P. S. Steyger et al., “Vanilloid receptors in hearing: altered cochlear sensitivity by vanilloids and expression of TRPV1 in the organ of corti,” *Journal of Neurophysiology*, vol. 90, no. 1, pp. 445–455, 2003.

[36] S. E. Myrdal and P. S. Steyger, “TRPV1 regulators mediate gentamicin penetration of cultured kidney cells,” *Hearing Research*, vol. 204, no. 1-2, pp. 170–182, 2005.

[37] R. S. Stepian, A. A. Indzhikulian, A. C. Vélez-Ortega et al., “TRPA1-mediated accumulation of aminoglycosides in mouse cochlear outer hair cells,” *Journal of the Association for Research in Otolaryngology*, vol. 12, no. 6, pp. 729–740, 2011.

[38] M. Jiang, H. Li, A. Johnson et al., “Inflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss,” *Science advances*, vol. 5, no. 7, article eaaw1836, 2019.

[39] H. E. Farris, C. L. LeBlanc, J. Goswami, and A. J. Ricci, “Probing the pore of the auditory hair cell mechanotransducer channel in turtle,” *The Journal of Physiology*, vol. 558, no. 3, pp. 769–792, 2004.

[40] M. E. Huth, A. J. Ricci, and A. G. Cheng, “Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection,” *International journal of otolaryngology*, vol. 2011, Article ID 937861, 19 pages, 2011.

[41] S. R. Kitcher, N. K. Kirkwood, E. D. Camci et al., “ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity,” *JCI Insight*, vol. 4, no. 15, 2019.

[42] A. Ricci, “Differences in mecano-transducer channel kinetics underlie tonotopic distribution of fast adaptation in auditory hair cells,” *Journal of Neurophysiology*, vol. 87, no. 4, pp. 1738–1748, 2002.

[43] A. J. Hudspeth, Y. Choe, A. D. Mehta, and P. Martin, “Putting ion channels to work: mecha-electrical transduction, adaptation, and amplification by hair cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 22, pp. 11765–11772, 2000.

[44] T. Hasson, P. G. Gillespie, J. A. Garcia et al., “Unconventional myosins in inner-ear sensory epithelia,” *The Journal of Cell Biology*, vol. 137, no. 6, pp. 1287–1307, 1997.

[45] S. N. Hobbie, S. Akshay, S. K. Kalapala, C. M. Bruell, D. Schicherabov, and E. C. Böttger, “Genetic analysis of interactions with eukaryotic RNA identify the mitoribosome as target in aminoglycoside ototoxicity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 52, pp. 20888–20893, 2008.

[46] H. Li, A. Kachelmeier, D. N. Furness, and P. S. Steyger, “Local mechanisms for loud sound-enhanced aminoglycoside entry into outer hair cells,” *Frontiers in Cellular Neuroscience*, vol. 9, p. 130, 2015.

[47] M. X. Guan, “Mitochondrial 12S rRNA mutations associated with aminoglycoside ototoxicity,” *Mitochondrion*, vol. 11, no. 2, pp. 237–245, 2011.

[48] J. Wang, S. Ladrech, P. Pujol, P. Brabet, T. R. Van De Water, and J. L. Puel, “Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss,” *Cancer Research*, vol. 64, no. 24, pp. 9217–9224, 2004.

[49] J. R. García-Berrocal, J. Nevado, R. Ramirez-Camacho et al., “The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear,” *British Journal of Pharmacology*, vol. 152, no. 7, pp. 1012–1020, 2007.

[50] C. Casares, R. Ramirez-Camacho, A. Trinidad, A. Roldán, E. Jorge, and J. R. García-Berrocal, “Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models,” *European Archives of Oto-Rhino-Laryngology*, vol. 269, no. 12, pp. 2455–2459, 2012.

[51] N. C. Schmitt, E. W. Rubel, and N. M. Nathanson, “Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate,” *The Journal of Neuroscience*, vol. 29, no. 12, pp. 3843–3851, 2009.

[52] S. Denamur, D. Tyteca, J. Marchand-Brynaert et al., “Role of oxidative stress in lysosomal membrane permeabilization
and apoptosis induced by gentamicin, an aminoglycoside antibiotic,” *Free Radical Biology & Medicine*, vol. 51, no. 9, pp. 1656–1665, 2011.

[53] D. Mukherjea, S. Ghosh, P. Bhatta et al., “Early investigational drugs for hearing loss,” *Expert Opinion on Investigational Drugs*, vol. 24, no. 2, pp. 201–217, 2015.

[54] N. D. Bonawitz, M. S. Rodeheffer, and G. S. Shadel, “Defective mitochondrial gene expression results in reactive oxygen species-mediated inhibition of respiration and reduction of yeast life span,” *Molecular and Cellular Biology*, vol. 26, no. 13, pp. 4818–4829, 2006.

[55] L. Astolfi, E. Simoni, F. Valent e et al., “Correction: coenzyme Q10 plus multivitamin treatment prevents cisplatin ototoxicity in rats,” *PLoS One*, vol. 12, no. 9, article e0185525, 2017.

[56] B. J. Conlon, J. M. Aran, O. P. Erre, and D. W. Smith, “Mitochondrial cell death eec-tration for Research in Otolaryngology, vol. 12, no. 5, pp. 2926–2930, 1998.

[57] H. So, H. Kim, Y. Kim et al., “Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1,” *Journal of the Association for Research in Otolaryngology*, vol. 9, no. 3, pp. 290–306, 2008.

[58] M. E. Peter and P. H. Krammer, “The CD95/CD16/Fas DISC and beyond,” *Cell Death and Differentiation*, vol. 10, no. 1, pp. 26–35, 2003.

[59] L. L. Cunningham, A. G. Cheng, and E. W. Rubel, “Caspase activation in hair cells of the mouse utricle exposed to neomycin,” *The Journal of Neuroscience*, vol. 22, no. 19, pp. 8532–8540, 2002.

[60] D. Bodmer, D. Brors, K. Pak, M. Bodmer, and A. F. Ryan, “Gentamicin-induced hair cell death is not dependent on the apoptosis receptor Fas,” *The Laryngoscope*, vol. 113, no. 3, pp. 452–455, 2003.

[61] S. Kothakota, T. Azuma, C. Reinhard et al., “Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis,” *Science*, vol. 278, no. 5336, pp. 294–298, 1997.

[62] W. H. Chung, S. H. Boo, M. K. Chung, H. S. Lee, Y. S. Cho, and S. H. Hong, “Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line,” *Acta Oto-Laryngologica*, vol. 128, no. 10, pp. 1063–1070, 2008.

[63] V. Borse, R. F. H. al Aameri, K. Sheehan et al., “Epileptogenesis of the lateral line,” *Kidney International*, vol. 58, no. 6, pp. 2525–2532, 2000.

[64] H. S. N. Sha and J. Schacht, “Protection from ototoxicity of intraperitoneal gentamicin in guinea pig.” *Kidney International*, vol. 58, no. 6, pp. 2525–2532, 2000.

[65] H. S. N. Sha and J. Schacht, “Salicylate attenuates gentamicin-induced ototoxicity,” *Laboratory Investigation*, vol. 79, no. 7, pp. 807–813, 1999.

[66] A. G. Cheng, L. L. Cunningham, and E. W. Rubel, “Mechanisms of hair cell death and protection,” *Current Opinion in Otolaryngology & Head and Neck Surgery*, vol. 13, no. 6, pp. 343–348, 2005.

[67] D. Brenner and T. W. Mak, “Mitochondrial cell death effectors,” *Current Opinion in Cell Biology*, vol. 21, no. 6, pp. 871–877, 2009.

[68] L. M. Leoni, Q. Chao, H. W. Cottam et al., “Induction of an apoptotic program in cell-free extracts by 2-chloro-2-deoxyadenosine 5'-triphosphate and cytochrome c,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 16, pp. 9567–9571, 1998.

[69] H. R. Stennicke and G. S. Salvesen, “Caspases - controlling intracellular signals by protease zymogen activation,” *Biochimica et Biophysica Acta*, vol. 1477, no. 1–2, pp. 299–306, 2000.

[70] L. L. Cunningham, J. I. Matsui, M. E. Warchol, and E. W. Rubel, “Overexpression of Bcl-2 prevents neomycin-induced hair cell death and caspase-9 activation in the adult mouse utricle in vitro,” *Journal of Neurobiology*, vol. 60, no. 1, pp. 89–100, 2004.

[71] A. B. Coffin, E. W. Rubel, and D. W. Raible, “Bax, Bcl2, and p53 differentially regulate neomycin- and gentamicin-induced hair cell death in the zebrafish lateral line,” *Journal of the Association for Research in Otolaryngology*, vol. 14, no. 5, pp. 645–659, 2013.

[72] M. Muzio, B. R. Stockwell, H. R. Stennicke, G. S. Salvesen, and V. M. Dixit, “An induced proximity model for caspase-8 activation,” *The Journal of Biological Chemistry*, vol. 273, no. 5, pp. 2926–2930, 1998.

[73] H. So, H. Kim, Y. Kim et al., “Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1,” *Journal of the Association for Research in Otolaryngology*, vol. 9, no. 3, pp. 290–306, 2008.

[74] M. E. Peter and P. H. Krammer, “The CD95/CD16/Fas DISC and beyond,” *Cell Death and Differentiation*, vol. 10, no. 1, pp. 26–35, 2003.

[75] L. L. Cunningham, A. G. Cheng, and E. W. Rubel, “Caspase activation in hair cells of the mouse utricle exposed to neomycin,” *The Journal of Neuroscience*, vol. 22, no. 19, pp. 8532–8540, 2002.

[76] D. Bodmer, D. Brors, K. Pak, M. Bodmer, and A. F. Ryan, “Gentamicin-induced hair cell death is not dependent on the apoptosis receptor Fas,” *The Laryngoscope*, vol. 113, no. 3, pp. 452–455, 2003.

[77] S. Kothakota, T. Azuma, C. Reinhard et al., “Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis,” *Science*, vol. 278, no. 5336, pp. 294–298, 1997.

[78] W. H. Chung, S. H. Boo, M. K. Chung, H. S. Lee, Y. S. Cho, and S. H. Hong, “Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line,” *Acta Otolaryngologica*, vol. 128, no. 10, pp. 1063–1070, 2008.

[79] V. Borse, R. F. H. al Aameri, K. Sheehan et al., “Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity,” *Cell Death & Disease*, vol. 8, no. 7, article e2921, 2017.

[80] W. Liu, H. Staecker, H. Stupak, B. Malgrange, P. Lefebvre, and T. R. Van De Water, “Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells,” *Neuroreport*, vol. 9, no. 11, pp. 2609–2614, 1998.

[81] T. Okuda, K. Sugahara, T. Takemoto, H. Shimogori, and H. Yamashita, “Inhibition of caspases alleviates gentamicin-induced cochlear damage in guinea pigs,” *Auris, Nasus, Larynx*, vol. 32, no. 1, pp. 33–37, 2005.

[82] J. I. Matsui, A. Haque, D. Hess et al., “Caspase inhibitors promote vestibular hair cell survival and function after aminoglycoside treatment in vivo,” *The Journal of Neuroscience*, vol. 23, no. 14, pp. 6111–6122, 2003.
[83] C. Borner, “The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions,” Molecular Immunology, vol. 39, no. 11, pp. 615–647, 2003.

[84] T. Lindsten, W. X. Zong, and C. B. Thompson, “Defining the role of the Bcl-2 family of proteins in the nervous system,” The Neuroscientist, vol. 11, no. 1, pp. 10–15, 2005.

[85] H. Xiang, Y. Kinoshita, C. M. Knudson, S. J. Korsmeyer, P. A. Schwartzkroin, and R. S. Morrison, “Bax involvement in p53-mediated neuronal cell death,” The Journal of Neuroscience, vol. 18, no. 4, pp. 1363–1373, 1998.

[86] S. Shimizu, Y. Eguchi, W. Kamiike et al., “Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 4, pp. 1455–1459, 1998.

[87] S. C. Pfannenstiel, M. Praetorius, P. K. Plinkert, D. E. Brough, P. Devarajan, M. Savoca, M. P. Castaneda et al., “Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways,” Hearing Research, vol. 174, no. 1-2, pp. 45–54, 2002.

[88] Y. H. Liu, X. M. Ke, Y. Qin, Z. P. Gu, and S. F. Xiao, “Adeno-associated virus-mediated Bcl-xL prevents aminoglycoside-induced hearing loss in mice,” Chinese Medical Journal, vol. 120, no. 14, pp. 1236–1240, 2007.

[89] H. M. Shen and Z. G. Liu, “JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species,” Free Radical Biology & Medicine, vol. 40, no. 6, pp. 928–939, 2006.

[90] J. I. Matsui, J. E. Gale, and M. E. Warchol, “Critical signaling events during the aminoglycoside-induced death of sensory hair cells in vitro,” Journal of Neurobiology, vol. 61, no. 2, pp. 250–266, 2004.

[91] K. Sugahara, E. W. Rubel, and L. L. Cunningham, “JNK signaling in neomycin-induced vestibular hair cell death,” Hearing Research, vol. 221, no. 1-2, pp. 128–135, 2006.

[92] J. E. Lee, T. Nakagawa, T. S. Kim et al., “Signaling pathway for apoptosis of vestibular hair cells of mice due to aminoglycosides,” Acta Oto-Laryngologica. Supplementum, vol. 124, pp. 69–74, 2004.

[93] L. P. Rybak and C. A. Whitworth, “Ototoxicity: therapeutic opportunities,” Drug Discovery Today, vol. 10, no. 19, pp. 1313–1321, 2005.

[94] U. Pirvola, L. Xing-Qun, J. Virkkala et al., “Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation,” The Journal of Neuroscience, vol. 20, no. 1, pp. 43–50, 2000.

[95] J. Wang, T. R. Van De Water, C. Bonny, F. de Ribaupierre, J. L. Puel, and A. Zine, “A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss,” The Journal of Neuroscience, vol. 23, no. 24, pp. 8596–8607, 2003.

[96] A. A. Eshraghi, J. Wang, E. Adil et al., “Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity,” Hearing Research, vol. 226, no. 1-2, pp. 168–177, 2007.